These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12169042)

  • 41. Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study.
    Vollmer T; Blight AR; Henney HR
    Clin Ther; 2009 Oct; 31(10):2215-23. PubMed ID: 19922892
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects.
    Chaikin P; Gillen MS; Malik M; Pentikis H; Rhodes GR; Roberts DJ
    Br J Clin Pharmacol; 2005 Mar; 59(3):346-54. PubMed ID: 15752381
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative activity of cetirizine and desloratadine on histamine-induced wheal-and-flare responses during 24 hours.
    Purohit A; Melac M; Pauli G; Frossard N
    Ann Allergy Asthma Immunol; 2004 Jun; 92(6):635-40. PubMed ID: 15237765
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Steady-state pharmacokinetics of once-daily cyclobenzaprine extended release: a randomized, double-blind, 2-period crossover study in healthy volunteers.
    Darwish M; Hellriegel ET
    Clin Ther; 2011 Jun; 33(6):746-53. PubMed ID: 21704239
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients.
    Bachert C; Kuna P; Sanquer F; Ivan P; Dimitrov V; Gorina MM; van de Heyning P; Loureiro A;
    Allergy; 2009 Jan; 64(1):158-65. PubMed ID: 19132976
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of diphenhydramine vs desloratadine and placebo in patients with moderate-to-severe seasonal allergic rhinitis.
    Raphael GD; Angello JT; Wu MM; Druce HM
    Ann Allergy Asthma Immunol; 2006 Apr; 96(4):606-14. PubMed ID: 16680933
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Desloratadine: A new, nonsedating, oral antihistamine.
    Geha RS; Meltzer EO
    J Allergy Clin Immunol; 2001 Apr; 107(4):751-62. PubMed ID: 11295678
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer.
    Robertson JF; Erikstein B; Osborne KC; Pippen J; Come SE; Parker LM; Gertler S; Harrison MP; Clarke DA
    Clin Pharmacokinet; 2004; 43(8):529-38. PubMed ID: 15170367
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical pharmacokinetics of mizolastine.
    Lebrun-Vignes B; Diquet B; Chosidow O
    Clin Pharmacokinet; 2001; 40(7):501-7. PubMed ID: 11510627
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study.
    Lasseter KC; Dilzer SC; Vargas R; Waldman S; Noveck RJ
    Clin Pharmacokinet; 2004; 43(2):121-9. PubMed ID: 14748620
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetics and safety of ebastine in healthy subjects and patients with renal impairment.
    Noveck RJ; Preston RA; Swan SK
    Clin Pharmacokinet; 2007; 46(6):525-34. PubMed ID: 17518511
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation.
    Abernethy DR; Barbey JT; Franc J; Brown KS; Feirrera I; Ford N; Salazar DE
    Clin Pharmacol Ther; 2001 Mar; 69(3):96-103. PubMed ID: 11240972
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bioavailability of two oral formulations of loratadine 20 mg with concomitant ketoconazole: an open-label, randomized, two-period crossover comparison in healthy Mexican adult volunteers.
    Piñeyro-López A; Pineyro-Garza E; Torres-Alanís O; Reyes-Araiza R; Gómez Silva M; Wacksman N; Lujàn Rangel R; de Lago A; Trejo D; Gonzàlez-de la Parra M; Namur S
    Clin Ther; 2006 Jan; 28(1):110-5. PubMed ID: 16490584
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The effect of 5-days of cetirizine, desloratadine, fexofenadine 120 and 180 mg, levocetirizine, loratadine treatment on the histamine-induced skin reaction and skin blood flow--a randomized, double-blind, placebo controlled trial].
    Kłos K; Kruszewski J; Kruszewski R; Sułek K
    Pol Merkur Lekarski; 2006 Nov; 21(125):449-53. PubMed ID: 17345838
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetic comparison of two nicotine transdermal systems, a 21-mg/24-hour patch and a 25-mg/16-hour patch: a randomized, open-label, single-dose, two-way crossover study in adult smokers.
    DeVeaugh-Geiss AM; Chen LH; Kotler ML; Ramsay LR; Durcan MJ
    Clin Ther; 2010 Jun; 32(6):1140-8. PubMed ID: 20637967
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The place of new antihistamines in allergy management. Apropos of desloratadine].
    Sabbah A
    Allerg Immunol (Paris); 2002 Dec; 34(10):377-83. PubMed ID: 12575624
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Desloratadine: an update of its efficacy in the management of allergic disorders.
    Murdoch D; Goa KL; Keam SJ
    Drugs; 2003; 63(19):2051-77. PubMed ID: 12962522
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of desloratadine on conjunctival allergen challenge-induced ocular symptoms.
    Torkildsen GL; Gomes P; Welch D; Gopalan G; Srinivasan S
    Clin Exp Allergy; 2009 Jul; 39(7):1052-9. PubMed ID: 19302250
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety evaluation of desloratadine in allergic rhinitis.
    González-Núñez V; Valero A; Mullol J
    Expert Opin Drug Saf; 2013 May; 12(3):445-53. PubMed ID: 23574541
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.